SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing
DNA-based cancer immunotherapies, will present emerging data from
its novel, multi-gene expression platform termed
Polycistronic Interleukin-12 Immune
Modulator (PIIM). The poster presentation entitled:
"Intratumoral administration of a multigene construct by
electroporation can effectively modulate anti-tumor response in a
murine B16.F10 model" (P403) will be presented during the
"Oncolytic Viruses and Intratumoral Therapies" session on
Friday, November 10th at
12:30-2:00 p.m and 6:30-8:00 p.m. ET
at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
2017, in National Harbor, MD.
The PIIM platform builds upon OncoSec's existing plasmid-based
cancer immunotherapy platform and may offer both enhanced
therapeutic activity as well as manufacturing efficiencies.
Preclinical data demonstrate the novel platform's flexibility to
add multiple immune modulating genes to alter the tumor
microenvironment which, when combined with electroporation in a
preclinical tumor animal model, resulted in regression of tumor
growth in both the treated primary lesion and a distant untreated
lesion.
"Immunotherapy has transformed the treatment of multiple
cancers, including melanoma; however, current agents do not help
all patients or have toxic side effects preventing broader use or
in combination with other agents," said Dan
O'Connor, CEO of OncoSec. "The ability to enhance response
with a simultaneous and potentially safe combination therapy,
including cytokines, checkpoint modulators, and antibodies, allows
the immune system to better recognize and attack the tumor, an
advantage of the PIIM platform versus other products currently
under development."
The full abstract is available and can be viewed on the STIC
website at www.sitcancer.org. The presentation is available in the
Publications section of OncoSec's website.
About the SITC Annual Meeting
The Society for Immunotherapy of Cancer (SITC) is a non-profit
medical professional society of influential scientists,
academicians, researchers, clinicians, government representatives,
and industry leaders from around the world dedicated to improving
cancer patient outcomes by advancing the science and application of
cancer immunotherapy. Currently, SITC has nearly 1,600
members representing 17 medical specialties and are engaged in
research and treatment of at least a dozen types of cancer. The
32nd SITC Annual Meeting & Associated Programs will take place
November 8-12, 2017 at the Gaylord
National Hotel & Convention Center in National Harbor, MD. For
more information, please go to http://www.sitcancer.org/2017.
About Polycistronic Interleukin-12 Immune Modulator
(PIIM)
PIIM represents an advancement for OncoSec's
plasmid-based cancer immunotherapy platform, coupling improved in
vivo electroporation with the ability to combine multiple
therapeutic molecules in a single DNA plasmid. The PIIM technology
platform offers expedited design and molecular cloning of these
molecules, individually or fused, with tailored effector functions
and relative expression levels. Delivery of multifunctional
combinations from a single plasmid backbone may also simplify the
manufacturing process.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer. ImmunoPulse
is designed to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as IL-12 (tavokinogene telseplasmid
[pIL-12] or "tavo"). In Phase 1 and 2 clinical trials,
ImmunoPulse® IL-12 has demonstrated a favorable safety
profile, evidence of anti-tumor activity in the treatment of
various solid tumors, and the potential to reach beyond the site of
local treatment to initiate a systemic immune response. OncoSec's
lead program, ImmunoPulse IL-12, is currently in clinical
development for metastatic melanoma and triple-negative breast
cancer. The program's current focus is on the significant unmet
medical need in patients with melanoma who are refractory or have
relapsed on anti-PD-1 therapies. In addition to tavo, the Company
is also identifying and developing new immune-targeting agents for
use with the ImmunoPulse platform. For more information, please
visit www.oncosec.com.
OncoSec Medical Incorporated Forward-Looking
Statements
This press release contains "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995, including statements about OncoSec's
business strategies, including advancement of its lead melanoma
program and its broader clinical portfolio and plans to pursue
collaborations with industry partners, as well as the potential
contributions and impact of new directors on these strategies. In
some cases, you can identify forward-looking statements by
terminology such as "may", "should", "expects", "plans",
"anticipates", "believes", "estimates", "predicts", "potential" or
"continue" or the negative of these terms or other comparable
terminology.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on
management's current preliminary expectations and are subject to
risks and uncertainties, which may cause OncoSec's results to
differ materially and adversely from the statements contained
herein. Potential risks and uncertainties that could cause actual
results to differ from those predicted include, among others, the
following: the status, progress and results of clinical programs;
ability to obtain regulatory approvals for, and the level of market
opportunity for, OncoSec's product candidates; OncoSec's business
plans, strategies and objectives, including plans to pursue
collaboration, licensing or other similar arrangements or
transactions; expectations regarding OncoSec's liquidity and
performance, including expense levels, sources of capital and
ability to maintain operations as a going concern; the competitive
landscape of OncoSec's industry; and general market, economic and
political conditions; and the other factors discussed in OncoSec's
filings with the Securities and Exchange Commission, including its
annual report on Form 10-K for the year ended July 31, 2017.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
disclaims any obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
Media Relations
OncoSec Medical Incorporated
media@oncosec.com
855.662.6732
Investor Relations
OncoSec Medical Incorporated
investors@oncosec.com
855.662.6732
Business Development
OncoSec Medical Incorporated
bd@oncosec.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/oncosec-announces-preclinical-data-demonstrating-multi-gene-expression-platform-for-delivery-of-multiple-cancer-immunotherapies-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting-2017-300552665.html
SOURCE OncoSec Medical Incorporated